1Jemal A,Murray T,Ward E,et al.Cancer stastistics 2005[J].CA Cancer J Clin,2005,55(1):10.
2D britz J,Preston R,H nfler J,et al.Follow-up study of K-ras mutations in the plasma of patients with pancreatic cancer:correlation withclinical features and carbohydrate antigen 19-9[J].Pancreas,2009,38(5):534.
3Lee SH,Lee SJ,Chung JY,et al.secreted by K-RasSnail pathway,is endocytosed by K-Ras-mutated cells;implication of target-specific drug delivery and early diagnostic marker[J].Oncogene,2009,28(19):2005.
4Lee SH,Lee SJ,Jung YS,et al.Blocking of p53-Snail binding,promoted by oncogenic K-Ras,recovers p53 expression and function[J].Neoplasia,2009,11(1):22.
9Pogue-Geile KL,Chen R,,Bronner MP,et al.Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism[J].PLo S Med,2006,3(12):e516.
3Seve P,Dumontet C. Chemoresistance in non-small lung cancer. Curr Med Chem Antieancer Agents,2005,5:73-88.
4Badran A, Yoshida A, Ishikawa K, et al. Identification of a novel splice variant of the human anti-apoptopsis gene survivin. Biochem Biophys Res Commun, 2004,314 : 902-907.
5Caldas H, Honsey LE, Altura RA, et al. Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer, 2005,4 : 11.
6Fangusaro JR,Jiang Y, Holloway MP, et al. Survivin, Survivin-2B, and Survivin-deltaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome. Br J Cancer, 2005,92 : 359-365.
7Tamm I,Wang Y,Sausville E,et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax,caspases,and anticancer drugs. Cancer Res,1998,58:5315- 5320.
8Suzuki A, Ito T, Kawano H, et al. Survivin initiates procaspase3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death. Oneogene, 2000, 19:1346-1353.
9Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature, 1998,396: 580- 584.
10Wheatley SP, Carvalho A, Vagnarelli P, et al. INCENP is required for proper targeting of Survivin to the centromeres and the anaphase spindle during mitosis. Curt Biol, 2001,11 : 886- 890.
3Jack C, Ivana S, Simon C, et al. Tamoxifen for prevention of breast cancer: extended long term follow-up of the IBIS-I breast cancer prevention trial[J].Lancet Oncol,2015; 16: 67-75.
4Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial[J].Lancet, 1998, 352:98-101.
5Powles TJ, Ashley S, Tidy A, et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial[J].J Natl Cancer Inst, 2007, 99: 283-290.
6Nichols HB, DeRoo LA, Scharf DR, et al. Risk-benefit profiles of women using tamoxifen for chemoprevention[J].JNCI J Natl Cancer Inst, 2015: 1-8.
7Visvanathan K, Hurley P, Bantug E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline[J].J Clin Oncol, 2013, 49(3122): 4361-4383.
8蔡德山. 抗乳腺癌药领跑者风头不减[N]. 医药经济报, 2015-1-28(4).
9Herold CI, Blackwell KL. The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer[J].Breast, 2008, 17(S1): S15-S24.
10Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer[J].J Clin Oncol, 2010, 28( 23) : 3784-3796.
